Medical Korea Brand Proclamation Ceremony & Symposium
8.10.2020 15:00:00 EEST | Business Wire | Press release
Since 2009, Korea has been promoting its medical competitiveness, and established a national medical brand titled “Smart Care, Medical Korea”, to represent the excellence of Korea’s medical services.
From 2009 to 2019, more than 2.76 million visitors from 190 countries around the world visited Korea to experience medical services. Also, Korea has provided a medical training program for international medical professionals from 31 different countries, sharing and expanding Korean medical system and resources across the world.
These efforts have been internationally recognized and received the “Health and Medical Tourism: Destination of the Year” award twice consecutively in 2018 and 2019 from the IMTJ Medical Travel Awards, a prestigious global medical tourism awards ceremony. In recognition of improving the reputation of Korea’s medical brands across the world and continuous dedication to enhancing healthcare, Korea was also awarded the “Porter Prize for Excellence in CSV”, named after a world-renowned business administration scholar, Michael E. Porter.
To address the recent global pandemic with the COVID-19, Medical Korea has renewed its brand to “Medical Korea, Where Your Days Begin Again” which emphasizes the humanitarian value of regaining the everyday life. Under this brand, Medical Korea will continue to stay at the forefront of achieving health and wellness for people around the world.
Korea Health Industry Development Institute (KHIDI) will announce the renewal of its brand and set a new direction for the healthcare industry during the COVID-19 era at the “Medical Korea Brand Proclamation Ceremony & Symposium”, held by the Ministry of Health and Welfare and organized by KHIDI, on October 14, 2020 (11:00~17:10, GMT+9).
The event will start with the keynote speech by Dr. Jerome Kim, Director General of the International Vaccine Institute (IVI), followed by presentations by Dr. Andrew Trister, Deputy Director of Digital Health and Innovation at Bill & Melinda Gates Foundation, and Hyung-gyoun (Harris) Byun, Vice President of KT. The presentations will shed light on the impact of the 4th industrial revolution in the medical service industry and will be aired live online. (https://www.medical-korea.org/eng/symposium/symposium.do)
About KHIDI
The Korea Health Industry Development Institute is a government-affiliated institution which provides the systematic and professional support for the improvement of public health and enhancement of the international competitiveness in the health industry.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201008005268/en/
Contact information
W Medical Strategy Group
US Representative
wgroup@wmedical.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Dream Accelerates Growth of Asset Management Platform With Acquisition of Chancerygate, a Leading U.K.-Based Industrial Asset Manager and Developer31.7.2026 01:09:00 EEST | Press release
Dream Unlimited Corp. (“Dream”) (TSX: DRM) today announced that Dream and Dream Industrial Real Estate Investment Trust (“Dream Industrial REIT”) (TSX: DIR.UN), have entered into definitive agreements for Dream to acquire Chancerygate Limited (“Chancerygate” or “CG”), a U.K.-based industrial developer and asset manager with a 30-year track record in the multi-let industrial (“MLI”) sector. Chancerygate currently manages a diversified portfolio of income producing and development assets totaling £1.2 billion ($2.2 billion). As part of the transaction, Dream will assume Chancerygate's investment management and development platform. Dream Industrial REIT will acquire Chancerygate's wholly owned real estate assets and co-investment interests across its managed ventures for consideration of approximately £78 million ($147 million), gross of certain in-place debt, and expects to fund an additional £25 million ($47 million) to complete the wholly owned development projects. The transactions a
Dream Industrial REIT Announces Entry Into U.K. Multi-Let Industrial Market and Growth of Strategic Private Ventures in Europe31.7.2026 01:06:00 EEST | Press release
Dream Industrial Real Estate Investment Trust (TSX: DIR.UN) (the “Trust” or the “REIT” or “DIR”) today announced that the Trust and Dream Unlimited Corp. (TSX: DRM) (“Dream”), have entered into definitive agreements for Dream to acquire Chancerygate Limited (“Chancerygate” or “CG”), a U.K.-based industrial developer and asset manager with a 30-year track record in the multi-let industrial (“MLI”) sector. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260730297448/en/ Audio Park, Sussex, UK - 104,000 sq ft As part of the transaction, Dream will assume Chancerygate's investment management and development platform. Dream Industrial REIT will acquire Chancerygate's wholly owned real estate assets and co-investment interests across its managed ventures for consideration of approximately £78 million ($147 million), gross of certain in-place debt on the wholly owned real estate assets, and expects to fund an additional £25 million
Rimini Street Announces Fiscal Second Quarter 2026 Financial and Operating Results30.7.2026 23:03:00 EEST | Press release
Rimini Street, Inc., (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced results for the fiscal second quarter ended June 30, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260730702735/en/ Rimini Street Announces Fiscal Second Quarter 2026 Financial and Operating Results “Second-quarter results and four consecutive quarters of improved growth metrics demonstrate strong demand for our core Rimini Support™ offering, increasing adoption of our broader enterprise software services portfolio and improving sales execution,” said Seth Ravin, president and CEO, Rimini Street. “Real innovation is not about installing a software vendor’s next ‘.ai’ release — it is about reducing total operating costs, improving profitability and enhancing competitive
Rimini Street Launches Rimini Govern™ for AI to Deliver Comprehensive AI Agent Governance, Security & Interoperability as a Service30.7.2026 23:01:00 EEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced the immediate availability of Rimini Govern™ for AI, the newest offering in the company’s Rimini Govern portfolio of Governance, Risk and Compliance (GRC) solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260730389723/en/ Rimini Street Launches Rimini Govern™ for AI to Deliver Comprehensive AI Agent Governance, Security & Interoperability as a Service The new managed service is delivered 24/7/365 through Rimini Street’s Global Command Centers by expert AI engineers to help organizations: Accelerate AI agent deployment Reduce AI agent operational risk Increase visibility into AI agent activity Provide AI agent activity audit capability Control AI agent operating costs Measure business value from AI agent investments Scale AI agent adoptio
One Biosciences Announces Data Validating New Method for Single-Cell Transcriptomic Tumor Profiling from Clinical Pathology Samples30.7.2026 22:03:00 EEST | Press release
One Biosciences, a techbio company pioneering clinical-grade single-cell tumor profiling, today announced data establishing that single-cell RNA expression profiles can be generated from the standard, formalin-fixed paraffin-embedded (FFPE) pathology specimens obtained in routine cancer care using the company’s proprietary platform, OneMap™. The study, conducted with collaborators at Centre Léon Bérard, Hôpital Bichat–Claude Bernard, Institut Curie, and Memorial Sloan Kettering Cancer Center, was released as a preprint on BiorXiv. “Every tumor is a unique ecosystem of many different types of cells, some cancerous, some not. Single cell profiling enables us to understand what those cells are, what they’re doing and potentially how that may impact treatment outcomes,” said Helena Yu, MD, thoracic medical oncologist at Memorial Sloan Kettering Cancer Center. “Until now that type of analysis required different types of samples and workflows than we deploy in clinical care. This study shows
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom